Chemistry:Lisaftoclax
From HandWiki
Lisaftoclax is an investigational new drug being developed by Ascentage Pharma for the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a selective inhibitor of the B-cell lymphoma 2 (BCL-2) protein, designed to restore the normal process of programmed cell death (apoptosis) in cancer cells.[1][2][3] As of 2024, lisaftoclax is undergoing multiple Phase 3 clinical trials, including studies in combination with BTK inhibitors for relapsed/refractory CLL/SLL.[2][4]
In July 2025, lisaftoclax was approved in China for the treatment of CLL or SLL in adult patients who had received at least one prior systemic therapy.[5]
References
- ↑ "Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy". Clinical Cancer Research 28 (24): 5455–5468. December 2022. doi:10.1158/1078-0432.CCR-21-4037. PMID 36048524.
- ↑ 2.0 2.1 "FDA Grants Clearance for Phase 3 Study of Lisaftoclax in Previously Treated CLL/SLL". 7 August 2023. https://www.onclive.com/view/fda-grants-clearance-for-phase-3-study-of-lisaftoclax-in-previously-treated-cll-sll.
- ↑ "Ascentage Pharma Announces New Drug Application for Lisaftoclax". PR Newswire (Press release). Retrieved 2024-11-23.
- ↑ "FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL". 8 August 2023. https://www.targetedonc.com/view/fda-clears-phase-3-trial-of-lisaftoclax-in-cll-sll.
- ↑ "Lisaftoclax: First Approval". Drugs 85 (12): 1635–1642. 2025. doi:10.1007/s40265-025-02251-4. PMID 41060518.
 |  |
